SCHEMBL72251

SCHEMBL72251

c1cc2c(o1)CCCC2

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20721261 0.97 TSHR (0.38)
SCHEMBL9123557 0.97 TSHR (0.38)
SCHEMBL3227687 0.95
SCHEMBL18576433 0.83
SCHEMBL2407590 0.78 PNMT (0.36)
SCHEMBL982394 0.73 HTR2C (0.47)
Hydrochloric Acid SCHEMBL8435409 0.72 PNMT (0.40)
Hydrochloric Acid SCHEMBL2999672 0.72 HTR2C (0.46)
SCHEMBL12947 0.69
SCHEMBL10395 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 851 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116514799-A Wee1 inhibitor, composition and application thereof 星希尔生物科技(上海)有限公司 2023-08-01 CN claimed
CN-110713475-B Novel synthesis method of polysubstituted 4, 5, 6, 7-tetrahydrobenzofuran 南京农业大学 2022-04-15 CN claimed
CN-110713475-A Novel synthesis method of polysubstituted 4,5,6, 7-tetrahydrobenzofuran 南京农业大学 2020-01-21 CN claimed
EP-3365418-A2 PARTICLES FOR MALODOR REDUCTION The Procter and Gamble Company (US) 2018-08-29 EP claimed
WO-2017070131-A2 PARTICLES FOR MALODOR REDUCTION THE PROCTER & GAMBLE COMPANY (US) 2017-04-27 WO claimed
US-20090029979-A1 5-HTX MODULATORS BIO-MEDISINSK INNOVASJON AS (NO) 2009-01-29 US claimed
EP-1781653-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS Astex Therapeutics Limited (GB) 2007-05-09 EP claimed
EP-1505966-A4 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2006-08-30 EP claimed
WO-2006003440-A1 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS ASTEX THERAPEUTICS LIMITED (GB) 2006-01-12 WO claimed
EP-1505966-A1 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS Bristol-Myers Squibb Company (US) 2005-02-16 EP claimed
US-20040254158-A1 Anticoagulants; atherosclerosis; strokes; thrombosis; cardiovascular disorders BRISTOL-MYERS SQUIBB COMPANY 2004-12-16 US claimed
WO-2003099276-A1 1,1-DISUBSTITUTED CYCLOALKYL DERIVATIVES AS FACTOR XA INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2003-12-04 WO claimed
US-5965740-A POTENT FUNGICIDAL AND INSECTICIDAL ACTIVITY; LOW TOXICITY SHIONOGI & CO., LTD. (JP) 1999-10-12 US claimed
EP-4741018-A2 SULPHONAMIDE COMPOUNDS Anaxis Pharma Pty Ltd (AU) 2026-05-13 EP disclosed
EP-4735425-A1 COMPOUNDS Psylo Pty Ltd (AU) 2026-05-06 EP disclosed
EP-4735441-A1 PYRROLOPYRIDINE COMPOUNDS FOR THE TREATMENT OF MENTAL ILLNESSES Psylo Pty Ltd (AU) 2026-05-06 EP disclosed
EP-0365484-B1 SULFAMOYL PHENYL UREAS CIBA-GEIGY AG (CH) 1993-01-07 EP disclosed
WO-1991004027-A1 NEW N-ARYL AND N-HETEROARYLAMIDE AND UREA DERIVATIVES AS INHIBITORS OF ACYL COENZYME A: CHOLESTEROL ACYL TRANSFERASE (ACAT) PFIZER INC. (US) 1991-04-04 WO disclosed
EP-0418071-A2 New N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase PFIZER INC. (US) 1991-03-20 EP disclosed
EP-0365484-A1 Sulfamoyl phenyl ureas CIBA-GEIGY AG (CH) 1990-04-25 EP disclosed